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ABSTRACT
Objective: The objective of present study was to assess the treatment pattern in the COVID-19 patients.
Methods: The present study was a hospital-based prospective observational conducted in Government Medical College Kathua (UT Jammu 
and Kashmir) on COVID-19 positive confirmed cases from December 2020 to January 2021. Consent was taken from patients who were willing 
to participate in the study. The details of presenting complaints and treatment received by them and outcome of management was recorded and 
evaluated from their treatment files.
Results: A total 56 patients of COVID-19 were enrolled for the study. Majority of them were males (60.71%) and maximum of the patients 
between 18 and 60 years constituted 69.6%. COPD (28.5%), severe anemia (21.42%), and diabetes mellitus and hypertension (19.64% each) were 
common comorbidities. Sore throat, dry cough, and breathlessness were common presenting symptoms. Pattern of antibiotics and antivirals revealed 
that azithromycin was frequently prescribed (87.5%) followed by hydroxychloroquine (44.64%), linzolid (21.42%), ceftriaxone (19.64%), and 
remdesivir (14.28%). Majority of patients (>50%) were treated with steroids, while all patients received multivitamins and Vitamin C (100%) and 
nearly 40% were administered zinc therapy.
Conclusions: Azithromycin, hydroxyquinine, remdesivir, and steroids were frequently prescribed in patients of COVID-19. Steroids were administered 
in oral, inhaler or in injection forms. Multivitamins including Vitamin C were given to all patients. Most of patients had comorbidities including COPD, 
diabetes mellitus type 2 and severe anemia.
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INTRODUCTION
Coronavirus disease 2019 (COVID-19) is the third viral infection after 
sever acute respiratory syndrome, (SARS) and Middle East respiratory 
syndrome originally reported from Asia [1,2]. The first case of COVID-19 
was identified in Wuhan, China in December 2019 and now pandemic 
worldwide. It is caused by a virus known as SARS corona virus-2 
and was initially named as novel coronavirus or 2019-N-COV [3]. 
India has currently the largest number of confirmed cases in Asia [4] 
and has the second highest number of confirmed cases in world after 
the United States of America. There have been 111,102,016 confirmed 
cases of COVID-19, including 2,462,911 deaths all over world till 
February 22, 2021. India has also recorded 11,005,850 confirmed cases 
and 156,385 deaths in India up to 22 february 2021 [5]. However, the 
death rate in our country is far less than developed world [6].
Infection occurs when virus-containing particles exhaled by an infected 
person, either as respiratory droplets or aerosols, get entry into the 
mouth, nose, or eyes of other person who is in close contact [7].
Symptoms of coronavirus disease often vary, but mostly people have 
fever, cough, breathing difficulties, fatigue, and loss of smell and taste. 
In severe cases kidney failure, high fever, multi organ failure, dyspnea, 
hypoxia is observed [8].
Although specific treatment eludes, but preventing measures play 
pivotal role in combating disease including physical or social distancing, 
frequent hand washing, quarantine, and ventilation of indoor spaces, 
face masking, avoiding public gathering, touching of eyes, nose, face by 
hands, healthy diet and lifestyle, and surface cleaning. Several vaccines 
have been developed and various countries have initiated mass 
vaccination campaign [9].
Symptomatic treatment is given in COVID-19 patients as there is no 
definitive therapy. It includes treatment of symptoms, supportive care, 
isolation, and experimental measures.
Drug controller of India on January 1, 2021, has approved the emergency 
or conditional use of Astra Zeneca’s COVID-19 vaccine, AZD 1222 
marketed as Covishield is developed by the University of Oxford in 
association with serum Institute Pune [10]. On January 2, 2021, vaccine 
BBV152 marketed as Covaxin developed by Bharat Biotech in association 
with Indian council of medical research and national institute of 
virology received approval from drug controller general of India for is 
emergency usage [11].
METHODS
A hospital-based observational study conducted in isolation ward and 
intensive care unit of Govt. Medical College Kathua in collaboration 
with the department of pharmacology.
Study population
A total of 56 patients were enrolled during span of 40 days of study, 
from ending of November 2020 to January 2021. Data were obtained 
by examining their case records sheets for treatment prescribed and 
demographic profile after obtaining consent.
Inclusion criteria
The following criteria were included in the study:
● PCR positive confirmed Covid-19 patients
● Patients More than 18 years of age
● Both genders.
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Exclusion criteria
The following criteria were excluded from the study:
● Multi organ failure
● Age <18 years
● Mentally retarded person.
Study approval
Approval of this study was obtained from institutional ethics committee 
before the start of this study (IEC/GMCK/64/pharmadt-27/8/2020).
Consent
Informed consent was taken from patients who were included in study.
RESULTS
A total of 56 patients were enrolled in study. Socio-demographic profile, 
medical histories were recorded from case files.
Demographic profile of patients revealed that most of them were males 
(60.71%). Majority of the patients were in the age group of 18–60 years 
(69.6%) in which 18–40 year age group contributed 32.1% while 
40–60 years age group contributed 37.5%. Most of the patient was 
under matric while 39.28% were undergraduate (Table 1).
Majority of the patients reported with sore throat (71.42%), dry 
cough (51%) and breathlessness (44.64%), and fever (28.57%) 
followed by generalized weakness, gastric upset, and malaise (Table 2).
Maximum number of the patients was having chronic obstructive 
lung disease (COPD) as comorbidity (28.5%), followed by severe 
anemia (21.42%), diabetes mellitus, and hypertension (19.64% each) 
(Table 3).
Pattern of antibiotics and antiviral revealed that azithromycin was 
frequently prescribed (87.5%), followed by hydroxychloroquine 
(44.64%), linezolid (21.42%), ceftriaxone (19.64%), and 
remdesivir (14.28%) (Table 4).
Steroids were frequently prescribed in these patients. Parenteral 
hydrocortisone was commonly prescribed (57.14%), followed by 
inhaler budicart 50% and dualin 46.2%. All patients were given 
multivitamin and Vitamin C. Majority of the patients also received 
pantoprazole (proton pump inhibitor 91.07%) antiemetic ondansetron 
was also given (Tables 5 and 6).
DISCUSSION
Since experience of mankind in management of COVID-19 disease 
is short, therefore the prescribing pattern in COVID-19 varied from 
country to country and many antiviral drugs and antimicrobials have 
been tried. In Indian setup also regimen varied. Therefore, it was thought 
of interest to evaluate the prescribing pattern in COVID-19 patients.
In the current study, demographic profile revealed that majority 
of patients were males (60.71%) and the most affected age group 
was between 18 and 60 years. The majority of patients were having 
education below matriculation (50%). Similar to our observations, 
other studies have also documented males to be predominantly 
affected with COVID-19 [12,13]. Perhaps, the reason for this may be due 
to increased mobility among males compared to females who mostly 
remain confined to their home in rural setup. Our hospital has majority 
of rural catchment where this pattern is quite prevalent.
The present study has revealed that sore throat (71.42%), dry 
cough (51.78%), and breathlessness (44.64%) were most common 
presenting complaints. All most all studies in past have shown 
similar presenting pattern of the disease with mild variation of 
symptoms [11,13,14]. Sore throat and dry cough is quite common 
presentation and is based on pathogenesis of coronavirus as it inflicts 
principally respiratory tracts [14].
In the current study, number of the COVID-19 patients had comorbidities. 
COPD was observed in 23.21%, followed by severe anemia (21.42%) 
and diabetes type-2 (19.64%). The diseases affecting lungs are known 
to predispose to COVID-19. COPD patients are at higher risk of more 
severe COVID-19 compared to patient without COPD [15].
Similarly severe anemia also predispose to COVID-19 disease. The 
pathophysiology of anemia and COVID-19 association is well explained 
when hemoglobin is low it results in less transportation of oxygen to 
various organs resulting in hypoxia. Hypoxia will ultimately result in 
Table 1: Demographic profile of patients
Basic parameters Frequency percentage









Under matric 28 50
Undergraduate 22 39.28
Postgraduate 6 10.71
Table 2: Symptoms of COVID-19 patients
Symptoms Frequency Percentage
Sore throat 40 71.42
Dry cough 29 51.78
Breathlessness 25 44.64
Fever 16 28.57
Productive cough 13 23.21
Weakness 11 19.64





Body aches 4 7.14
Chest pain 4 7.14
Table 3: Comorbidities in COVID-19 patients
Comorbidities Frequency Percentage
Chronic obstructive lung disease 13 23.21
Severe anemia 12 21.42
Hypertension 11 19.64
Type 2 diabetes mellitus 11 19.64
Dysfunctional uterine bleeding 3 5.35
Pelvic inflammatory disease 3 5.35
Pulmonary hypertension 2 3.57
Pancreatic carcinoma 1 1.78
Table 4: Pattern of antiviral/antimicrobials in COVID patients
Medication Frequency Percentage
Tab. Azithromycin 49 87.5
Tab. Hydroxychloroquine 25 44.64
Inj. Linezolid 12 21.42
Inj. Ceftriaxone 11 19.64
Tab. Doxycycline 10 17.85
Inj. Ceftriaxone+Tazobactam 8 14.28
Tab. Remdesivir 8 14.28
Inj. Ceftriaxone+Sulbactum 6 10.71
Inj. Meropenem 5  8.92
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multi organ dysfunction especially the respiratory organ dysfunction 
making more vulnerable to COVID-19 [16].
Diabetes was a frequent comorbidity in our study (19.64%). Number 
of studies has documented that DM patients are predisposed to the 
infections including COVID-19 [17,18]. Recently, studies have also 
found that even death rate was higher among COVID-19 patients with 
diabetes [19-21].
Among antibiotics the azithromycin (87.5%) was frequently prescribed 
followed hydroxychloroquine (44.64%), injection linezolid (21.42%), 
inj. ceftriaxone (19.64%), and injection meropenem (8.92%). Similar 
to our results numerous research workers have shown azithromycin 
and hydroxychloroquine to be most frequently prescribed in 
COVID-19 patients [12,22-24].
However, our study results are in contrast to other trial where 
third-generation cephalosporins (i.e., ceftriaxone) (53.8%), meropenem 
(40.9%), moxifloxacin (29.5%), and doxycycline (25.4%) [25] were the 
four most prescribed antibiotics among participating patients.
Azithromycin, in addition to its antibacterial macrolide activity, has 
also antiviral and immunomodulation properties. These actions 
make azithromycin frequent choice in management of inflammatory 
manifestations of coronavirus involving lungs [26].
Antiviral remdesivir was prescribed in only eight patients (14.2%). 
This is in contrast to western literature where the remdesivir was more 
frequently prescribed [27]. The lesser proportion of prescribing of 
remdesivir in our study compared to developed countries could be due 
to higher cost of and less availability. Since our institution catchment 
area has majority population with poor economic status; therefore, it 
is not surprising that antiviral was less prescribed. However, central 
government has recently issued directions to cut down the price 
and enhance more production of remdesivir so that it is available to 
masses [28].
Steroids were also given in most of the COVID-19 patients. The steroids 
reduce inflammation (swelling) and mucus production in the airway of 
lungs. Steroids have been shown to have beneficial effect in moderate to 
severe COVID-19 diseased in indoor admitted patients [29,30].
In the present study, vitamins were prescribed in all patients. Number 
of studies has also shown similar pattern. Vitamins in addition to 
restore deficiency have antioxidant role. Most of studies have also 
demonstrated similar pattern [31,32].
Studies conducted in other countries have revealed that statins, 
angiotensin converting enzyme inhibitor, anticoagulant mostly 
formed the bulk of medication in contrast to our country. Statins 
are known for their pleiotropic anti-inflammatory, antithrombotic, 
and immunomodulatory effects. They may have a potential role as 
adjunctive therapy to mitigate endothelial dysfunction and deregulated 
the inflammation in patients with COVID-19 infection [33].
Two patients in our study group died due to bilateral COVID-19 
pneumonia. Both patients had ground glass appearance in lungs. 
Bilateral lungs involvement is highly fatal in COVID-19 disease. Various 
studies have recorded similar pattern [11,34].
CONCLUSIONS
Azithromycin and hydroxyquinine were more frequently given than 
remdesivir, steroids were almost given to all patients as inhaler, injection. 
Other drugs like multivitamins were prescribed in all patients. Most of 
patients of COVID-19 had comorbidities COPD, diabetes mellitus type 2 
and severe anemia were common comorbidities.
Limitations
Our study has some limitations. Less number of patients has been 
taken. COVID- 19 positive patients who were admitted in other centers 
than GMC Kathua were not included in the study.
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